Rinsulin NPC, 100 me/ml suspension 10 ml

Pharmacotherapeutic group

Hypoglycemic agent, insulin of medium duration of action

Code A10AC01.

Pharmacological properties

Pharmacodynamics.

Rinsulin^® NPX is human insulin produced using recombinant DNA technology. It is a medium-acting insulin. It interacts with specific receptor of outer cytoplasmic cell membrane and forms insulin-receptor complex, which stimulates intracellular processes, including synthesis of several key enzymes (hexokinase, pyruvate kinase, glycogen synthase and others).

Lower blood glucose content is due to increased intracellular transport, increased absorption and assimilation by tissues, stimulation of lipogenesis and glycogenesis and decreased rate of glucose production by liver.

The duration of action of insulin drugs is mainly determined by the speed of absorption, which depends on several factors (e.g., the dose, route and place of administration), so the action profile of insulin is subject to significant variations both in different people and the same person.

On average, after subcutaneous administration, Rinsulin^® NPC begins to act after 1.5 hours, with maximal effect developed between 4 and 12 hours, the duration of action is up to 24 hours.

Pharmacokinetics

The completeness of absorption and onset of effect of insulin depends on the place of administration (stomach, thigh, buttocks), dose (volume of insulin administered), the concentration of insulin in the drug, etc. Distributed irregularly in tissues; does not penetrate through placental barrier and into breast milk. It is broken down by insulinase mainly in the liver and kidneys. It is excreted by the kidneys (30-80%).

Indications

Diabetes mellitus type 1.
Diabetes mellitus type 2 stage of resistance to oral hypoglycemic agents, partial resistance to these drugs (during combination therapy), intercurrent diseases.
Type 2 diabetes mellitus in pregnant women.

Pharmacological effect

Pharmacotherapeutic group

Hypoglycemic agent, intermediate-acting insulin

CodeATX-A10AC01.

Pharmacological properties

Pharmacodynamics.

Rinsulin® NPH is a human insulin produced using recombinant DNA technology. Intermediate acting insulin. It interacts with a specific receptor on the outer cytoplasmic membrane of cells and forms an insulin-receptor complex that stimulates intracellular processes, including the synthesis of a number of key enzymes (hexokinase, pyruvate kinase, glycogen synthase, etc.).

The decrease in blood glucose content is due to an increase in its intracellular transport, increased absorption and assimilation by tissues, stimulation of lipogenesis, glycogenesis, a decrease in the rate of glucose production by the liver, etc.

The duration of action of insulin preparations is mainly determined by the rate of absorption, which depends on several factors (for example, dose, route and site of administration), and therefore the insulin action profile is subject to significant fluctuations, both between different people and within the same person.

On average, after subcutaneous administration, Rinsulin® NPH begins to act within 1.5 hours, the maximum effect develops between 4 and 12 hours, the duration of action is up to 24 hours.

Pharmacokinetics

The completeness of absorption and the onset of the effect of insulin depends on the injection site (abdomen, thigh, buttocks), dose (volume of insulin administered), insulin concentration in the drug, etc. It is unevenly distributed throughout the tissues; does not penetrate the placental barrier and into breast milk. It is destroyed by insulinase mainly in the liver and kidneys. Excreted by the kidneys (30-80%).

Special instructions

Do not use the drug if, after shaking, the suspension does not become white and uniformly cloudy.

Active ingredient

Insulin-isophane human genetically engineered

Composition

1 ml of the drug contains:

Contraindications

Increased individual sensitivity to insulin or any of the components of the drug.
Hypoglycemia.

Side Effects

Caused by the effect on carbohydrate metabolism: hypoglycemic conditions (pallor of the skin, increased sweating, palpitations, tremors, chills, hunger, agitation, paresthesia of the oral mucosa, weakness, headache, dizziness, decreased visual acuity). Severe hypoglycemia can lead to the development of hypoglycemic coma.

Interaction

There are a number of medications that affect the need for insulin.

Overdose

In case of an overdose of the drug, a hypoglycemic state may develop. The initial symptoms of a hypoglycemic state are a sudden increase in sweating, palpitations, tremor, hunger, agitation, paresthesia in the mouth, pallor, headache. In severe cases of overdose, hypoglycemic coma may develop.

Treatment: the patient can eliminate mild hypoglycemia himself by ingesting sugar or carbohydrate-rich foods. In severe cases, 20 – 40 ml of 40% glucose solution is administered intravenously, 1 mg of glucagon is administered intramuscularly.

Storage conditions

In a dark place at a temperature from +2°C to 4-8°C.
Avoid freezing.

Shelf life

2 years.

Manufacturer

Geropharm LLC, Russia